 |
[Alpha Biz=(Chicago) Reporter Paul Lee] Samsung BioLogics surpassed the consensus in the second quarter of this year, exceeding KRW 1.58 trillion in sales in the first half for the first time since its foundation. The operating profit ratio was close to 40 percent.
This is due to orders from large overseas pharmaceutical companies such as Pfizer, Roche and Novartis based on the world's largest production facilities. Samsung BioLogics plans to continue to grow its facility investment.
Samsung BioLogics said on the 26th that its operating profit and sales were tentatively tallied at 445.2 billion won and 1.5871 trillion won based on consolidated financial statements in the first half of this year. Operating profit increased 29% and sales 36% compared to the same period last year.
Performance in the first half is the largest ever. Samsung BioLogics explained that its operating profit and sales increased sharply due to long-term large-scale orders for supplies and maximizing efficiency through full operation of plants 1 to 3. As it recorded its best performance in the first half of the year, it is also expected to surpass last year's sales of 3 trillion won.
Consolidated operating profit for the second quarter is 253.4 billion won and sales are 866.2 billion won. Operating profit increased 49% from the same period last year, and sales increased 33%.
Based on the separate financial statements, operating profit for the second quarter is 254.1 billion won and sales are 637.2 billion won. The operating profit ratio is 39.87%.
AlphaBIZ 폴 리(hoondork1977@alphabiz.co.kr)
